Close

BIO letter to Rep. Michael Bilirakis, Chairman, Energy & Commerce Cmte., Subcommittee on Health

Regarding the proposed approval of generic biologics.

Building biotech in Ohio, You can if you think you can

We are still a young industry, but we have grown-up issues.

Statement of J. Craig Venter, PhD, President, Celera Genomics

On Behalf of the Biotechnology Industry Organization Before the Subcommittee on Consumer Protection, U.S. House Committee on Energy and Commerce.

House Energy and Commerce Committee Testimony

By Thomas Okarma, CEO, Geron, Subcommittee on Health

Testimony of Thomas Okarma, PhD, MD President and CEO of Geron Corporation On Behalf of Biotechnology Industry Organization (BIO) Before the Subcommittee on Crime, House Judiciary Committee

By Thomas Okarma, CEO, Geron, Subcommittee on Crime

Prescription Drug Benefits as Part of Medicare Modernization

The Biotechnology Industry Organization (BIO) supports amendment of the current reexamination authority to enhance patent quality.

Letter to Mr. Nicholas Godici

Acting Undersecretary of Commerce and Acting Director of the United States Patent and Trademark Office Regarding Patent Law Harmonization

Testimony of Carl B. Feldbaum Before the Senate Commerce Committee Subcommittee on Science, Technology and Space

By Carl B. Feldbaum, President, BIO, Subcommittee on Science, Technology and Space

PTO response to Carl Feldbaum on International Patent Harmonization Efforts

Disclosure of Information

The Biotechnology Industry Organization (BIO) is pleased to submit comments to the Food and Drug Administration (FDA) on the proposed rule "Availability for Public Disclosure and Submission to FDA for Public Disclosure of Certain Data and Information Related to Human Gene Therapy or Xenotransplantation." 66 Fed. Reg. 4688 (January 18, 2001) (the Proposed Rule or FDA’s Proposal).